Business Context and Reporting Period
Company: Black Hawk Acquisition Corporation (Black Hawk)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended November 30, 2025
Business Overview: Black Hawk is a Cayman Islands exempted company formed as a Special Purpose Acquisition Company (SPAC) to effect a merger, share exchange, or asset acquisition with one or more target businesses. The Company has no operating revenue and relies on interest income from its Trust Account and related party loans to fund operations.
Key Transaction: On April 26, 2025, the Company entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. The transaction values Vesicor at a pre-money equity value of $70 million. The deal is subject to shareholder approval, regulatory approvals, and Nasdaq listing approval.
Key Financial Metrics
| Metric | Year Ended Nov 30, 2025 | Year Ended Nov 30, 2024 |
|---|---|---|
| Net Income | $1,329,557 | $1,915,703 |
| Interest Income (Trust Account) | $2,258,631 | $2,484,264 |
| General & Administrative Expenses | $795,510 | $492,131 |
| Related Party Administrative Fees | $120,000 | $83,945 |
| Cash and Cash Equivalents | $39,521 | $264,842 |
| Investments Held in Trust Account | $23,827,149 | $71,829,264 |
| Working Capital Deficit | ($1,431,443) | N/A (Positive in 2024) |
| Deferred Underwriting Fee Payable | $2,415,000 | $2,415,000 |
| Convertible Notes (Related Party) | $595,369 | $0 |
Material Changes vs. Prior Period
- Significant Redemptions: In connection with a shareholder vote on July 8, 2025, to extend the business combination deadline, holders of 4,775,923 public shares exercised redemption rights. Approximately $51.0 million was withdrawn from the Trust Account, reducing the balance from ~$71.8 million to ~$23.8 million.
- Extension of Combination Period: Shareholders approved an extension allowing the Company to extend the deadline month-by-month from June 22, 2025, through December 22, 2026. This requires monthly deposits of $150,000 into the Trust Account.
- Liquidity Position: The Company moved from a positive working capital position in 2024 to a working capital deficit of $1.43 million in 2025 due to the redemption of public shares and increased operating expenses.
- Debt Financing: The Company issued convertible promissory notes to its Sponsor totaling $600,000 in 2025 (June and September notes) to fund extension payments and working capital. As of November 30, 2025, the outstanding principal balance was $595,369.
- Target Company Contribution: Vesicor Therapeutics contributed $575,000 to the Company to cover extension costs, recorded as "Due to target company."
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has determined that the Company's liquidity needs and the uncertainty of completing a business combination raise substantial doubt about its ability to continue as a going concern. The financial statements do not include adjustments that might result from this uncertainty.
- Extension Funding: The Company must deposit $150,000 per month into the Trust Account to extend the deadline. While the Company is current as of the filing date, some payments in late 2025 and early 2026 were funded after their due dates. Future funding is not guaranteed.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of November 30, 2025, due to a material weakness involving inadequate segregation of duties and insufficient written policies.
- Transaction Risks: The proposed business combination with Vesicor is subject to customary closing conditions, including shareholder approval and Nasdaq listing. There is no assurance the transaction will be consummated.
- Related Party Conflicts: Officers and directors have pre-existing fiduciary obligations to other entities. They are required to present suitable business opportunities to those entities first, though they have agreed to present opportunities to Black Hawk if rejected by others.
Investor Verification Checklist
- Extension Payment Status: Verify that the $150,000 monthly extension payments are being funded on time to avoid liquidation.
- Transaction Closing Conditions: Monitor the status of shareholder votes and Nasdaq listing approvals required for the Vesicor Therapeutics merger.
- Trust Account Balance: Confirm the current balance in the Trust Account ($23.8 million as of Nov 30, 2025) and the per-share redemption value (~$11.22).
- Related Party Debt: Review the terms of the convertible notes held by the Sponsor and the target company's contribution to ensure no dilution or repayment issues arise.
- Internal Control Remediation: Assess the Company's plan to remediate the material weakness in internal controls over financial reporting.